Reduced-Intensity Conditioning Allogeneic Transplantation from Unrelated Donors: Evaluation of Mycophenolate Mofetil Plus Cyclosporin A as Graft-versus-Host Disease Prophylaxis  by Pérez-Simón, Jose A. et al.
Biology of Blood and Marrow Transplantation 14:664-671 (2008)
Q 2008 American Society for Blood and Marrow Transplantation
1083-8791/08/1406-0001$32.00/0
doi:10.1016/j.bbmt.2008.03.007Reduced-Intensity Conditioning Allogeneic
Transplantation from Unrelated Donors: Evaluation of
Mycophenolate Mofetil Plus Cyclosporin A as Graft-
versus-Host Disease Prophylaxis
Jose A. Perez-Simon,1 Rodrigo Martino,2 Dolores Caballero,1 David Valcarcel,2 Noemi Rebollo,6 Rafael de la
Camara,3 Javier Perez de Oteiza,4 Inmaculada Heras,5 Maria V. Calvo,6 Jordi Sierra,2 Jesus F. San Miguel1
1Servicio de Hematologıa, Hospital Clınico Universitario de Salamanca; 2Hospital Santa Creu i Sant Pau, Barcelona,
Spain; 3Hospital de la Princesa, Madrid, Spain; 4Hospital Ramon y Cajal, Madrid, Spain; 5Hospital Morales Meseguer,
Murcia, Spain; and 6Servicio de Farmacia, Hospital Clınico Universitario de Salamanca, Spain, on behalf of the Grupo
Espan˜ol de Trasplante Hematopoyetico (GETH)
Correspondence and reprint requests: Jose A Perez-Simon, MD, PhD, Servicio de Hematologıa, Hospital Clınico
Universitario de Salamanca, Paseo de San Vicente 37007, Salamanca, Spain (e-mail: pesimo@usal.es).
Received February 21, 2008; accepted March 19, 2008
ABSTRACT
In the current study, we have analyzed the efficacy of cyclosporine A (CSA) plus mycophenolate mofetil (MMF)
as graft-versus-host disease (GVHD) prophylaxis in the fludarabine plus melphalan or busulfan reduced inten-
sity regimen (RIC) setting in a series of 44 patients receiving allogeneic transplantation from an unrelated donor.
Only 23% were in the first complete remission at the time of transplant. Cumulative incidence of grades II-IV
and III-IV acuteGVHD (aGVHD) was 53% and 23%, respectively. Fifty-six percent had equal to or greater than
grade 2 gut involvement. Cumulative incidence of overall and extensive chronic GVHD (cGVHD) was 93% and
63%, respectively. Ninety-two percent of patients who were evaluable 1100 days after transplant were in com-
plete remission. Relapse rate was 25% at 2 years. Event free (EFS) and overall survival (OS) at 2 years were 52%.
Pharmacokinetic assays of mycophenolic acid (MPA) showed a therapeutic area under the curve (AUC) at the
dosage of 3 g daily, although a large inter- and intraindividual variations of MPA plasma levels were found. In
conclusion, the combination of CSA plus MMF in the fludarabine plus melphalan or busulfan RIC setting is fea-
sible. RegardingGVHD, this combination allowed to control aGVHDbut lead to a high incidence of cGVHD, so
that newer strategies are required, especially in trying to decrease gastrointestinal involvement.
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Allogeneic transplantation is the most effective ap-
proach for the treatment of many patients diagnosed
with hematologic malignancies [1,2]. The number of
donors available from international registries allows
to find an appropriate unrelated donor for a high
percentage of patients [3], and results of unrelated do-
nor transplantation have improved through the last
years [4,5], which is because of a better patient and do-
nor selection [3,6], a better prophylaxis against infec-
tious episodes [7,8], and a better management664of graft-versus-host disease (GVHD) [9,10], resulting
in outcomes similar to those reported among patients
receiving hematopoietic transplantation from related
donors [11-13]. Nevertheless, results in the long term
are still hampered by a high transplant-related toxic-
ity [14,15], and this is especially true for older
patients, those who have received a prior transplant,
or those with a history of fungal infection or other
comorbid conditions [15-17]. In an attempt to reduce
treatment-related mortality (TRM) in this subset of
patients, many studies have been reported using
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(RIC) allogeneic transplantation. Unfortunately, no
prospective studies have been conducted comparing
the outcome of patients receiving myeloablative versus
RIC. Moreover, within the nonmyeloblative or RIC
setting, different conditioning regimens have been de-
veloped, ranging from truly nonmyeloablative, usually
based on low dose total body irradiation (TBI), to
more intense conditionings based on combinations
of fludarabine plus melphalan or busulfan [18-26]. In
addition, GVHD prophylaxis greatly varies in differ-
ent trials so that, currently, there is no RIC or
GVHD prophylaxis, which can be considered as stan-
dard or optimal. Interestingly, cyclosporine A (CSA)
plus methotrexate (MTX) in combination or not
with anti-T monoclonal antibodies (mAb) have mostly
been used in the RIC setting, whereas CSA plus myco-
phenolate mofetil (MMF) have beenmainly used in the
context of nonmyeloablative/low-dose TBI-based reg-
imens [18-26]. The latter GVHD prophylaxis was de-
veloped to induce a higher immunosupression that
allowed the hematopoietic engraftment after truly
nonmyeloablative conditionings. The only study pro-
spectively comparing CSA plus MTX versus CSA
plus MMF showed a faster engraftment and lower tox-
icity using MMF, with no significant differences in
terms of GVHD [27], although this study did not in-
clude a large number of patients. In addition, MMF
has been used as an effective approach for the treat-
ment of GVHD.
With this background, we performed a clinical
trial using RIC based on fludarabine plus melphalan
or busulfan andCSA plusMMF asGVHDprophylaxis
instead of our standard approach in the RIC setting
based on CSA plus MTX, in a series of 44 patients re-
ceiving allogeneic transplantation from an unrelated
donor.
PATIENTS AND METHODS
Patients Characteristics and Trial Desing
Forty-four patients from 5 different institutions in
Spain were included in the trial TNE-ANM 2001 for
the Grupo Espan˜ol de Trasplante (GETH). Patients’
characteristics are specified in Table 1, the most
common diagnosis being acute myelogenous leukemia
(AML) in 13 patients, non-Hodgkin lymphoma
(NHL) in 8 patients, and myelodysplastic syndromes
(MDS) in 7 patients. Fitfy-two percent of the patients
were not in complete remission (CR) at the time of trans-
plant, and only 23% were in first CR. Among patients
younger than 40 years the reason to undergo RIC was:
relapse to a prior autograft (n5 8), severe pneumopathy
(n5 1), poor performance status (n5 1), active infection
(n 5 1), and heavily pretreated (n 5 1).
The aim of this phase II trial was to analyze event-
free survival (EFS), GVHD, and TRM of the fludara-bine plus busulfan or melphalan conditioning regimen
using CSA plus MMF instead of our conventional
approach for GVHD prophylaxis in the RIC setting
based on CSA plus MTX. Stopping rules included:
TRM of 3 of the first 5 or 6 of the first 10 patients,
acute GVHD (aGVHD) grade III or higher in 3 of 5
or 6 of 10 patients, graft failure in 2 of 5 or 3 of 10 pa-
tients, and patients recruitment lower than 10 patients
in the first 18 months after protocol approval.
Initially it was planned to recruit 30 patients in 36
months, although the recruitment period was in-
creased and 44 patients were finally included.
Conditioning Regimen and GVHD Prophylaxis
Two RIC regimens were used: 1 recommended for
lymphoid malignancies, and 1 for myelogenous malig-
nancies. The lymphoid RIC regimen consisted of flu-
darabine 30 mg/m2 administered intravenously on
days 29 to 25, followed by melphalan 70 mg/m2 in-
travenously on days23 and22. The myeloid regimen
consisted of the same doses of fludarabine together
with busulfan 1 mg/kg for 10 doses (days26 to24, to-
tal 10 mg/kg), with phenytoin given as anticonvulsant
prophylaxis.
Hematopoietic stem cells from an unrelated donor
were infused on day 0. A single HLAmismatched of 10
was allowed at the allele level. Of the 44 patients, 14 re-
ceived hematopoietic stem cells from mismatched do-
nors, 13 had a single allele mismatched at HLA class I,
and 1 at HLA class II level.
Stem cell source was bone marrow in 53% and pe-
ripheral blood in 47% of the patients.
Table 1. Patients Characteristics
Characteristics N 5 44 (%)
Diagnosis
Acute myelogenous leukemia 13
Acute lymphoblastic leukemia 5
Myelodysplastic syndrome 7
Chronic lymphocytic leukemia/
prolymphocytic leukemia
3
Chronic myelogenous leukemia 2
Non-Hodgkin lymphoma 8
Multiple myeloma/Waldenstro¨m 4
Myelofibrosis 2
Disease status at transplant
First complete remission 10 (23%)
.First complete remission 11 (25%)
First partial response 2 (5%)
.First partial response 4 (9%)
Active disease 9 (20%)
Progressive disease 4 (9%)
Others (aplasia post chemotherapy) 4 (9%)
Age: median (range) 48 (17-60)
Sex:
Male* 29 (66%)
Female 15 (34%)
Previous transplantation 19 (43%)
*Sex mismatched among male patients: 43%.
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for all patients. CSA was given at a dose of 1 mg/kg
per day intravenously from days 27 to 22, and then
3 mg/kg/day intravenously or orally from day 21.
Levels were maintained in the therapeutic range until
tapering. MMF was given at a dose of 1 g every 12
hours for the first 10 patients and 1 g every 8 hours
thereafter. In the case that patients did not tolerate
oral medications, intravenous MMF was used at
a dose of 15 mg/kg either every 12 hours or every 8
hours. The dose was planned to be tapered starting
on day156 and stopped on day1100, although it var-
ied depending on the chimerism status or the develop-
ment of GVHD.
aGVHD and chronic GVHD (cGVHD) were
graded by established criteria [28,29].
MMF Monitoring
Drug concentration-time data were used to deter-
mine mycophenolic acid (MPA) pharmacokinetics
from 8 patients included in 1 of the participating cen-
ters. At least 1 complete pharmacokinetic profile was
obtained from each patient. For this purpose 8 to 9
blood samples were collected just prior to as well as
0.5, 1, 2, 3, 4, 6, 8, and 12 hours afterMMF administra-
tion. Five milliliters of blood anticoagulated with
EDTA were centrifuged at 2000 rpm for 10 minutes,
and the plasma was removed. The enzyme multiplied
immunoassay technique (EMIT) for the determination
of total MPA was performed on a Viva-E analyzer
(Dade Behring, Germany). There was no adjustment
ofMMFdose based uponMPAplasma concentrations.
All assays were performed in the same laboratory.
Statistical Analysis
Events analyzed were calculated from the time of
transplantation using Kaplan-Meier product-limit es-
timates. TRM was defined as death because of causes
unrelated to the underlying disease, and relapsing pa-
tients were censored at the time of relapse. EFS was
calculated from transplant until disease progression
or death and those patients who did not reach disease
response (complete or partial remission) any time after
transplant were considered events on day 100, because
that was the first date for complete disease evaluation.
Overall survival (OS) was calculated from transplant
until death. Kaplan-Maier estimates were used to ana-
lyze the impact on EFS and OS of sex, sex mismatch,
age, diagnosis, disease status at transplant, source of
progenitor cells, aGVHD and cGVHD.
Patients who had evidence of engraftment were
evaluable for aGVHD, whereas patients who engrafted
and survived more than 100 days were evaluable for
cGVHD.Theday of aGVHDwas calculated from trans-
plant until diagnosis of aGVHD among evaluable pa-
tients and the same for cGVHD. Cumulative incidenceestimates for GVHDwas performed taking into account
death as competing risk. GVHD-related mortality was
defined as death because of causes directly related to
GVHD, and those deaths attributed to immunosupres-
sion in patients requiring treatment for GVHD were
also considered as GVHD related mortality.
Noncompartmental analysis was used for calcula-
tion of pharmacokinetic parameters. The area under
the curve (AUC) for the dosing interval was calculated
by the log-trapezoidal rule using a proprietary com-
puter program.
Data were analyzed by statistical software SPSS
version 13.0 (SPSS Inc., Chicago, IL). Differences
were considered to be statistically significant when
P-values were\.05 and a 2-sided test was used.
RESULTS
Regimen-Related Toxicity and GVHD
Regimen was well tolerated. Extrahematologic
toxicity was mild, with only 9% of patients developing
grade 3 mucositis, 3% grade 3 nausea or vomiting, and
5% grade 3 liver toxicity. The median number of days
with neutrophil counts\1000/mm3 was 9 days, and
with platelet counts\20,000/mm3was 7 days. Patients
reached.1000/mm3 granulocytes and.20,000 plate-
lets/mm3 at 18 and 12 days after transplant, respec-
tively. No significant differences were observed in
terms of extra-hematologic toxicity or engraftment
between both preparative regimens.
aGVHD flared at a median of 25 days (range: 10-
103 days) after transplant. Cumulative incidence of
grades II-IV and III-IV aGVHD was 53% and 23%,
respectively (Figure 1A). Out of the 29 patients who
developed aGVHD, 17 (58%) had greater than or
equal to grade 2 skin involvement, 16 (56%) had
greater than or equal to grade 2 gut involvement, and
6 (21%) had greater than or equal to grade 2 liver in-
volvement. Fifty-six percent of patients reached com-
plete remission of aGVHD after first line treatment.
cGVHD flared at a median of 118 days (range: 97-
1057 days) after transplant. Cumulative incidence of
overall and extensive cGVHD was 93% and 63%, re-
spectively (Figure 1B). Among the most frequently in-
volved organs, there were mucosal involvement in
63% of cases, skin was affected in 53%, gut in 41%,
and liver in 31% of patients with cGVHD. After first
line treatment 21% of patients obtained complete re-
mission and 47% of patients reached partial response.
A univariate analysis for grades II-IV aGVHD and
extensive cGVHD was performed including the fol-
lowing variables: age, sex, diagnosis, sex mismatched,
CD34 cell count, HLA disparity, use of melphalan or
busulfan in the conditioning regimen, and source of
progenitor cells (plus prior aGVHD in univariate
analysis for the risk of extensive cGVHD). Use of bu-
sulfan or melphalan influenced the risk of GVHD
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Figure 1. Cumulative incidence of acute and chronic GVHD.with 46% versus 62% incidence of grades II-IV
aGVHD among patients receiving the prior or the
latter, respectively, P 5 .055. One or the other drug
was used depending on patients diagnosis, the same
values were obtained upon comparing patients diag-
nosed with myeloid versus lymphoid malignancies, re-
spectively. Finally, patients sex marginally influenced
on the incidence of aGVHD (cumulative incidence of
66% versus 47% grades II-IV aGVHD for male versus
female recipients, respectively, P 5 .09).
Only prior aGVHD significantly influenced on the
incidence of cGVHD in univariate analysis, with a cu-
mulative incidence of extensive cGVHD of 87% ver-
sus 67% among patients with prior grades II-IV
aGVHD or not, respectively, P 5 .01.
Chimerism and Drug Monitoring
Chimerism assays showed complete chimerism in
bone marrow in 80%, 90%, and 82% of patients ana-
lyzed on days121,150, and1100 after transplant, re-spectively. In peripheral blood these figures were 57%,
72%, and 82% in lymphocytes and 75%, 90%, and
86% in granulocytes.
The pharmacokinetic parameters for each patient
as well as mean (and SD) values are shown in Table
2. A therapeutic AUC0-24h, according to the
recommended range for renal transplants (70-140
mg*h/mL), was observed in 9 of 12 pharmacokinetic
profiles at the dosage of 3 g daily. Coefficient of varia-
tion for total MPA trough concentrations was higher
than that obtained for AUC, 55.46% versus 34.12%,
respectively. Large inter- and intraindividual varia-
tions of MPA plasma levels were found, as shown in
Figure 2. By contrast, no significant differences were
observed in pharmacokinetic parameters depending
on the route of administration, because no evidence
for enterohepatic circulationwas observed in the AUC.
Route of administration or AUC did not signifi-
cantly influenced on the risk of aGVHD or cGVHD.
These data are summarized in Table 2.Table 2. Mycophenolic Acid Pharmacokinetic Parameters
Patient
Day after
Transplant aGVHD cGVHD
MMF Administration
Interval (Hours)
Administration
Route
Cmin
(mg/mL)
AUC0-tau
(mg*h/mL)
AUC0-24h
(mg*h/mL)
1 10 Grade 2 limited 12 oral 0.5 30.10 60.2
2 6 Grade 2 limited 8 oral 0.9 32.73 98.19
2 13 8 oral 1.5 51.12 153.36
3 8 No limited 8 intravenous 0.5 34.01 102.03
3 20 8 intravenous 0.5 22.97 68.91
4 8 Grade 1 No 8 intravenous 1.2 35.30 105.9
4 37 8 oral 2.6 43.01 129.03
5 15 Grade 3 extensive 8 oral 1.6 37.09 111.27
6 3 Grade 3 limited 8 intravenous 1.3 25.05 75.15
6 25 8 intravenous 0.4 20.89 62.67
6 34 8 intravenous 1.0 30.56 91.68
7 7 Grade 2 Non evaluable 8 intravenous 1.5 66.39 199.17
8 97 No limited 8 intravenous 0.9 42.15 126.45
Mean 1.11 36.26 106.46
SD 0.61 12.37 39.24
Cmin indicates trough concentration; AUC0-tau, area under the curve for the dosing interval; AUC0-24h, area under the curve for 24 hours; SD,
standard deviation; AUC0-tau, 38.81 mg*h/mL for oral versus 34.66 mg*h/mL for intravenous administration, P 5 .21
AUC0-24h, 110.41 mg*h/mL for oral versus 103.9 mg*h/mL for intravenous administration, P 5 .33.
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Figure 2.Concentration versus time profile of mycophenolic acid in 8 patients after oral or intravenousMMF administration. Patients 2, 3, and 6
are highlighted to show the high intraindividual variation of MPA pharmacokinetics.Disease Response and Outcome
Ninety-two percent of patients who were evaluable
1100 days after transplant were in complete remis-
sion. Relapse rate was 25% at 2 years. Of the 8 patients
who relapsed after transplant, 3 had active disease at
the time of transplant and 3 had already relapsed to
a prior autograft.
Overall TRMwas 42% (Figure 3). Causes of death
are summarized in Table 3. In univariate analysis only
patients sex significantly influenced in TRM (68% ver-
sus 32% for males versus females, respectively; P 5
.007). EFS and OS at 2 years was 52% (Figure 4A
and B). None of the variables analyzed significantly
influenced on overall survival (OS).
DISCUSSION
MMF is being commonly used in the GVHD
prophylaxis within the nonmyeloablative transplant
setting. Nevertheless, in the fludarabine/melphalan-
based RIC setting information regarding the use of
CSA plus MMF is scanty. In this setting, Rodriguez
et al. [30] have previously reported similar results to
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Figure 3. Transplant related mortality.those shown in the current trial, with 32% TRM at
1 year, 63% incidence of grades II-IV aGVHD, and
73% cGVHD. In our study we found that, although
the incidence of aGVHD was not higher than ex-
pected, cGVHD flared in 93% of patients, and most
of them developed extensive forms of cGVHD. Inter-
estingly, the gut was affected in 51% of patients who
developed aGVHD and 41% of those with cGVHD,
suggesting that GVHD prophylaxis was suboptimal
at the gastrointestinal level. On the contrary, the liver
was only involved in 21% of cases, which indicates that
the efficacy of this type of GVHD prophylaxis varied
depending on the targeted organ. Compared to the in-
cidence of GVHD reported in the truly nonmyeloa-
blative setting using the same prophylaxis, Maris
et al. [31] have reported 52% incidence of grades II-
IV aGVHD and 37% cGVHD, which is significantly
lower compared to that reported using RIC, both by
Rodriguez et al. [30] and in the current study. Interest-
ingly, it has been shown that myeloablative condition-
ing increases the risk of aGVHD compared to RIC
[32] or nonmyeloablative [33] allogeneic transplanta-
tion. According to the current results, even within
the nonmyeloablative versus RIC setting, the dose of
chemotherapy may be important to determine the
risk of GVHD. In this regard, and considering the ef-
ficacy of the procedure to obtain disease control, we
found an OS and EFS of 52% at 2 years, similar to
that reported by Rodriguez et al. [30], and also similar
to the results described by Kalh et al. [34] using non-
myeloablative conditioning. Of note, in the latter
study, OS was 26% at 3 years among patients diag-
nosed with Hodgkin disease, RAEB, or acute leuke-
mia, with disease status more advanced than CR,
which was because of a high relapse rate of 57% at 3
years. In the current study, we did not find a higher re-
lapse rate in this subset of patients, suggesting again
that, also for disease control, the dose of chemotherapy
does matter in the nonmyeloablative versus RIC set-
ting, as previously suggested by de Lima et al. [35].
Compared to other studies using RIC, in the current
study we found a higher incidence of cGVHD
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Day
Postrasplant Cause of Death Diagnosis Prior Autograft
Pretrasplant Comorbid
Condition Age
38 Adenovirus 1 GVHD NHL Yes 24
51 Cranial hemorraghe Waldenstro¨n 51
52 Interstitial pneumonitis AML Yes 40
89 Septic shock NHL Yes 52
94 GVHD Prolymphocitic
leukemia
59
96 Aspergillus MDS 45
98 Liver failure RAEB Liver disease; ICU
prior admission
59
158 Adenovirus NHL Yes 56
160 Heart failure 1GVHD RAEB Cardiopathy 60
169 CMV disease AML Yes aspergillus 23
215 Interstitial pneumonitis AML Yes Severely affected
pulmonary function
tests
22
236 GVHD ALL 45
237 GVHD NHL 54
479 Lung GVHD AML Yes Severely affected
pulmonary function
tests
59
GVHD indicates graft-versus-host disease; NHL, non-Hodgkin lymphoma; AML, acute myelogenous leukemia; MDS, myelodisplastic syn-
drome; RAEB, refractory anemia with excess of blasts; ICU, intensive care unit.compared to that reported using CAMPATH-1H [25]
or rapamycin [36], although, as previously shown, the
development of cGVHD may influence on disease
control after transplantation [18,37,38]. In our own ex-
perience [18,32,37,38], the incidence of both aGVHD
and cGVHDwas also higher with the current protocol
compared to previous studies using CSA plus MTX.
Nevertheless, contrary to the current trial, only
matched related donors (MRD) were used. Using flu-
darabine plus melphalan and GVHD prophylaxis with
CSA plus MTX, de Lima et al. [35] reported 39%
grades II-IV and 19% grades III-IV aGVHD, whereas
53% of patients developed cGVHD. Again, these fig-
ures compare favorably with those observed in the cur-
rent study using CSA plus MMF, but 40% of patients
received allogeneic transplantation from MRD in the
de Lima study. Among patients receiving allogeneic
transplantation from 10/10 matched unrelated donors,the French Society of BMT and Cellular Therapy [39]
reported 60% and 29% incidence of grades 2-4 and 3-
4 aGVHD using CSA plus MTX in the myeloablative
setting. This incidence is similar to that reported in the
current study with an older patients population.
Finally, regarding drug monitoring, a therapeutic
window for MPA has not been accurately established,
either for AUC or for predose concentration. In our
pharmacokinetic study, we found that most patients
reached a therapeutic AUC0-24h, according to the rec-
ommended range for renal transplants (70-140 mg*h/
mL) [40], at dosage of 1 g every 8 hours, which sug-
gests that the administration of MMF every 12 hours,
as recommended among patients receiving solid organ
transplantation, may lead to suboptimal levels in the
hematopoietic transplant setting. These results are in
accordance to those reported by Giaccone et al. [41],
and could be attributed to a poorer absorption rate,52%
42%
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Figure 4. Event free and overall survival.
670 J. A. Perez-Simon et al.because of mucositis or intestinal GVHD. Moreover,
a higher clearance has been observed among patients
undergoing hematopoietic stem cell transplantation.
Similar to previous reports, we found an extensive in-
ter- and intraindividual variability of MPA pharmaco-
kinetics [42-44]. Coefficient of variation for total MPA
trough concentrations was higher than that observed
for AUC (55.46% versus 34.12%, respectively). Ac-
cordingly, the AUC could be a more reliable pharma-
cokinetic parameter for MPA drug monitoring in
clinical practice.
In the current study neither route of administra-
tion nor the AUC significantly influenced on the risk
of aGVHD or cGVHD, although the low number of
cases precluded to draw any conclusion in this regard.
In conclusion, the combination of CSA plus MMF
in the fludarabine plus melphalan or busulfan RIC
setting is feasible. The regimen allows to obtain dis-
ease control in a high-risk population of patients. Re-
garding GVHD, this combination allowed control of
aGVHD but lead to a high incidence of cGVHD, so
that newer strategies are required, especially trying
to decrease gastrointestinal involvement.
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